ITMI992197A1 - 10-FORMILTETRAIDROFOLATO DEIDROGENASI - Google Patents
10-FORMILTETRAIDROFOLATO DEIDROGENASI Download PDFInfo
- Publication number
- ITMI992197A1 ITMI992197A1 IT1999MI002197A ITMI992197A ITMI992197A1 IT MI992197 A1 ITMI992197 A1 IT MI992197A1 IT 1999MI002197 A IT1999MI002197 A IT 1999MI002197A IT MI992197 A ITMI992197 A IT MI992197A IT MI992197 A1 ITMI992197 A1 IT MI992197A1
- Authority
- IT
- Italy
- Prior art keywords
- enzyme
- treatment
- liver
- doses
- deae
- Prior art date
Links
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108010091861 Formyltetrahydrofolate dehydrogenase Proteins 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 5
- 230000003013 cytotoxicity Effects 0.000 claims description 4
- 231100000135 cytotoxicity Toxicity 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000283707 Capra Species 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008366 buffered solution Substances 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000007796 conventional method Methods 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Description
Descrizione dell'invenzione industriale avente per titolo: Description of the industrial invention entitled:
" 1 O-FORMILTETRAIDROFOL ATO DEIDROGENASI COME AGENTE TERAPEUTICO” "1 O-FORMYLTETRAIDROFOL ATO DEHYDROGENASE AS A THERAPEUTIC AGENT"
La presente invenzione riguarda l'uso di 10-formiltetraidrofolato deidrogenasi come agente terapeutico, in particolare come agente citotossico e antitumorale. The present invention relates to the use of 10-formyltetrahydrofolate dehydrogenase as a therapeutic agent, in particular as a cytotoxic and antitumor agent.
La 10-formiltetraidrofolato deidrogenasi è un enzima, presente nel fegato e nel sistema nervoso di mammiferi, di cui non è stato finora descritto alcun uso terapeutico. 10-formyltetrahydrofolate dehydrogenase is an enzyme, present in the liver and nervous system of mammals, of which no therapeutic use has so far been described.
Il cDNA di 10-formiltetraidrofolato deidrogenasi di ratto è stato descritto in J. Biol. Chem. 266(8), 4965-4973, 1991, mentre più recentemente è stato descritto il cDNA dello stesso enzima umano (Biochem. Mol. Biol. Int., 47(3), 407-415, 1999). Rat 10-formyltetrahydrofolate dehydrogenase cDNA was described in J. Biol. Chem. 266 (8), 4965-4973, 1991, while more recently the cDNA of the same human enzyme has been described (Biochem. Mol. Biol. Int., 47 (3), 407-415, 1999).
Metodi per la preparazione deU'enzima ricombinante sono inoltre noti da Protein Expression Purif. 6, 457-64, 1995 e Biochem. J. 306(3), 651-5, 1995. Methods for the preparation of the recombinant enzyme are also known from Protein Expression Purif. 6, 457-64, 1995 and Biochem. J. 306 (3), 651-5, 1995.
Si è ora trovato che la 10-formiltetraidrofolato deidrogenasi di mammifero è in grado di indurre, se somministrata a pazienti o animali portatori di tumori, una marcata risposta citotossica nei confronti di cellule tumorali. It has now been found that mammalian 10-formyltetrahydrofolate dehydrogenase is capable of inducing, if administered to patients or animals carrying tumors, a marked cytotoxic response towards tumor cells.
Tale citotossicità sembra mediata da anticorpi citotossici nei confronti di cellule di tumori umani, in particolare di carcinomi e adenocarcinomi. This cytotoxicity appears to be mediated by cytotoxic antibodies against human tumor cells, particularly carcinomas and adenocarcinomas.
La citotossicità è qualificabile in vitro su cellule HT-29, Kato III e Cytotoxicity is qualifiable in vitro on HT-29, Kato III e
Claims (1)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1999MI002197 IT1314197B1 (en) | 1999-10-20 | 1999-10-20 | 10-Formyltetrahydrofolate dehydrogenase, useful as a therapeutic agent, particularly as an antitumor agent possessing high cytotoxicity |
AU59695/00A AU5969500A (en) | 1999-06-03 | 2000-06-02 | 10-formyltetrahydrofolate dehydrogenase as therapeutical agent |
PCT/EP2000/005066 WO2000074711A2 (en) | 1999-06-03 | 2000-06-02 | 10-formyltetrahydrofolate dehydrogenase as therapeutical agent |
DE60004819T DE60004819T2 (en) | 1999-06-03 | 2000-06-02 | 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE AS A THERAPEUTIC AGENT |
JP2001501245A JP2003501398A (en) | 1999-06-03 | 2000-06-02 | 10-formyltetrahydrofolate dehydrogenase as therapeutic agent |
EP00945698A EP1181046B1 (en) | 1999-06-03 | 2000-06-02 | 10-formyltetrahydrofolate dehydrogenase as therapeutical agent |
ES00945698T ES2204649T3 (en) | 1999-06-03 | 2000-06-02 | `10-FORMILTETRAHYDROPHOLATE DEHYDROGENASE AS A THERAPEUTIC AGENT. |
AT00945698T ATE247976T1 (en) | 1999-06-03 | 2000-06-02 | 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE AS A THERAPEUTIC AGENT |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1999MI002197 IT1314197B1 (en) | 1999-10-20 | 1999-10-20 | 10-Formyltetrahydrofolate dehydrogenase, useful as a therapeutic agent, particularly as an antitumor agent possessing high cytotoxicity |
Publications (3)
Publication Number | Publication Date |
---|---|
ITMI992197A0 ITMI992197A0 (en) | 1999-10-20 |
ITMI992197A1 true ITMI992197A1 (en) | 2001-04-20 |
IT1314197B1 IT1314197B1 (en) | 2002-12-06 |
Family
ID=11383818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT1999MI002197 IT1314197B1 (en) | 1999-06-03 | 1999-10-20 | 10-Formyltetrahydrofolate dehydrogenase, useful as a therapeutic agent, particularly as an antitumor agent possessing high cytotoxicity |
Country Status (1)
Country | Link |
---|---|
IT (1) | IT1314197B1 (en) |
-
1999
- 1999-10-20 IT IT1999MI002197 patent/IT1314197B1/en active
Also Published As
Publication number | Publication date |
---|---|
ITMI992197A0 (en) | 1999-10-20 |
IT1314197B1 (en) | 2002-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1958643B1 (en) | Stable formulations containing enhancing proportions of gamma- and alpha-interferons | |
NO20053424L (en) | Improved pharmaceutical botulinum toxin preparations. | |
CN109312313A (en) | For treating the mRNA therapy of ornithine transcarbamylase deficiency disease | |
JPH0770195A (en) | Sugar-modified interferon | |
BR0009043A (en) | Compound, pharmaceutical composition, and method of treating a disease in an animal in which the activity of the cysteine protease contributes to the pathology and / or symptomatology of the disease | |
CA2376894C (en) | Pharmaceutical composition comprising a protein and an ectoine | |
ES2322234T3 (en) | MODIFIED CITOCINES FOR USE IN CANCER THERAPY. | |
Guo et al. | Head-to-tail macrocyclization of albumin-binding domain fused interferon alpha improves the stability, activity, tumor penetration, and pharmacology | |
EP1684681B1 (en) | A mixture for transdermal delivery of low and high molecular weight compounds | |
US20200268666A1 (en) | Polynucleotides encoding coagulation factor viii | |
EP1173476A4 (en) | Soybean protein nutraceuticals | |
ITMI992197A1 (en) | 10-FORMILTETRAIDROFOLATO DEIDROGENASI | |
WO1999002120A3 (en) | Compositions and methods for reversibly increasing permeability of biomembranes | |
ES2326530T3 (en) | MODIFIED CITOCINES FOR USE IN CANCER THERAPY. | |
US20220323542A1 (en) | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR | |
ES2204649T3 (en) | `10-FORMILTETRAHYDROPHOLATE DEHYDROGENASE AS A THERAPEUTIC AGENT. | |
CN115702159A (en) | NGR conjugates and uses thereof | |
On et al. | Pathways for drug delivery to the central nervous system | |
EA026453B1 (en) | Use of oxidised avidin for inhalation | |
JP3522798B2 (en) | Method for producing sugar-modified protein | |
US20230158100A1 (en) | Treatment of panx1 associates diseases | |
JPH01246226A (en) | Stable composition containing modified asparaginase | |
WO2024078729A1 (en) | Placenta expressed proteins for use in the treatment of tendon injury | |
JP2000109434A (en) | Inhibition of cell growth and cell growth inhibitor | |
ITMI982634A1 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON PROTEINS. |